Medicortex Finland Oy

Medicortex Finland Oy Announces the Progression of Clinical Trial for Detection of Mild Traumatic Brain Injury in Children

Share

TURKU, Finland. Medicortex Finland Oy announces the progression of clinical trial for detection of mild Traumatic Brain Injury (TBI) and concussion. Company’s third clinical trial is focusing on children and adolescents, and the recruitment of patients is taking place at Satasairaala hospital in Finland. The first patients with head injury and the first healthy controls have been enrolled in the study.

Medicortex Finland Oy tiedottaa lasten ja nuorten tapaturmaisten aivovammojen diagnostiikkaan liittyvän kliinisen tutkimuksen etenemisestä. Yrityksen kolmas kliininen tutkimus toteutetaan Satasairaalassa Porissa. Ensimmäiset päänsä loukanneet potilaat ja terveet verrokit on rekrytoitu tutkimukseen.

“A diagnostic kit for rapid detection of mild TBI in children is important. It will satisfy the pressing need to improve the detection of brain injury in children who suffered a head injury” said Dr. Mårten Kvist, Medical Director of Medicortex Finland Oy. The rapid diagnostic kit ProbTBITM, currently being developed by Medicortex, will help to diagnose brain injury especially in patients who don’t show visible symptoms of brain damage - which is frequently the case with concussion and mild injury.

The clinical trial is conducted at Satasairaala hospital in Pori – the main hospital in Satakunta region with the first level pediatric emergency department and expertise in the TBI management. Body fluid samples are collected from young patients (0 – 17 years) with suspected mild TBI, and the samples will be studied with respect to a specific biomarker signature following a head injury. The Principal Investigator, Dr. Sari Malmi, Head of the Department of Pediatric Surgery, says that a new test for improving the diagnosis of traumatic brain injury is highly needed. It will improve the examination of young patients with a traumatic brain injury and thus improve the quality of their treatment.

"ProbTBITM will be a highly innovative diagnostic kit for rapid detection of concussion. Children in particular will benefit from it since they can be refrained from radiation or sedation which are needed for the CT scan of the head, as well as from an exposure to other sick patients in the hospital" said Dr. Adrian Harel, CEO of Medicortex. “Participation of the young patients shortly after a head injury will be a challenge, but we have a committed and skilled clinical team working with us in the hospital” Dr. Harel adds.

In this clinical trial, Medicortex will collect a sufficient number of pediatric samples in order to prove the applicability of the brain injury test in children, as an expected continuation for previously proven clinical performance in adults. The clinical trial is posted at the public database ClinicalTrials.gov with identifier NCT04288167.

Medicortex Finland Oy is engaged in the development of first-of-its-kind diagnostic kit for rapid detection of concussion and mild TBI from non-invasive body fluid samples. The Company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. The patent portfolio held by Medicortex secures exclusivity to develop the product. More information about TBI and its detection is available on Company's website at www.medicortex.fi

Keywords

Contacts

Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
adrian.harel@medicortex.fi

Links

About Medicortex Finland Oy

Medicortex Finland Oy
Medicortex Finland Oy
Itäinen Pitkäkatu 4 B
20520 TURKU

http://www.medicortex.fi

Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence and severity of a head injury.

Subscribe to releases from Medicortex Finland Oy

Subscribe to all the latest releases from Medicortex Finland Oy by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Medicortex Finland Oy

Medicortex Finland Oy Announces the Advancement in Clinical Trial for Detection of Mild Traumatic Brain Injury in Children31.8.2020 15:43:39 EESTPress release

TURKU, Finland. Medicortex Finland Oy announces achievement of the halfway in the clinical trial for detection of mild traumatic brain injury (TBI) and concussion in children and adolescents. Company's third clinical trial is being conducted at Satasairaala hospital in Finland. About 50% of the target number of head injury patients and healthy controls have already been enrolled in the study which started in March this year.

Medicortex Finland Oy:lle tutkimusrahoitusta Yhdysvaltain Puolustusministeriöltä3.7.2019 14:00:00 EESTTiedote

Turku, 03.07.2019. Medicortex Finland Oy:lle on myönnetty Yhdysvaltain puolustusministeriön 1,1 miljoonan dollarin tutkimusrahoitus. Rahoituksen avulla yhtiö jatkaa ProbTBITM -aivovammatestin kliinistä kehitystyötä. Tämä vahvasti kilpailtu rahoitus on samalla myös tunnustus Medicortexin teknologian ja tuotteen kyvylle vastata kasvavaan tarpeeseen määrittää tapaturmainen aivovamma tai aivotärähdys nopeasti ja luotettavasti.

Urheilulääketieteen asiantuntija Medicortex Finland Oy:n neuvonantajaksi10.12.2018 11:10:44 EETTiedote

Medicortex Finland Oy tiedottaa, että lääketieteen tohtori (LT) Markku Tuominen on liittynyt yhtiön Tieteellis-kliiniseen neuvottelukuntaan. Tuominen toimii Medisport Oy:n yrittäjänä ja ylilääkärinä. Lisäksi LT Tuominen toimii Kansainvälisen Jääkiekkoliiton lääketieteellisen valiokunnan jäsenenä sekä Suomen Jääkiekkoliiton lääkärinä. Tuominen on väitellyt Tampereen yliopiston Lääketieteen ja biotieteiden tiedekunnasta vuonna 2017 aiheena jääkiekkovammat MM- ja olympiaturnauksissa.